Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest - LARVOL DELTA

Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea. (PubMed, Hum Vaccin Immunother) - "Compared to vaccination of girls only with the quadrivalent HPV vaccine, gender-neutral vaccination with the nonavalent HPV vaccine was projected to prevent 1,282,415 cases of cervical intraepithelial neoplasia grade 1 (CIN1), 918,384 cases of CIN2/3, 36,248 cases of cervical cancer, and 9,313 cervical cancer deaths in females over 100 years...The incremental cost-effectiveness ratio (ICER) was ₩38.9 million per quality-adjusted life year (QALY), which is below the accepted cost-effectiveness threshold in South Korea. These findings suggest that gender-neutral vaccination with the nonavalent HPV vaccine would reduce the public health burden of HPV disease in both females and males in South Korea and would be cost-effective under base case assumptions about vaccine price and coverage of boys."

HEOR • Journal • Anal Carcinoma • Cervical Cancer • Dermatology • Genito-urinary Cancer • Gynecology • Head and Neck Cancer • Oncology • Penile Cancer • Solid Tumor

Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study. (PubMed, BMC Public Health) - "The cost-effective strategy for each vaccine type was vaccination combined with three-year VIA screening compared with the current situation. Comparing the three optimal strategies, it was found that bivalent HPV vaccine combined with three-year VIA screening is the most cost-effective prevention strategy at this stage when the willingness to pay is low, and with the gradual increase in willingness to pay, the nine-valent HPV vaccine combined with three-year VIA screening will become the optimal prevention strategy. It is recommended that the Chinese government consider gradually increasing the vaccination coverage of domestically produced bivalent HPV vaccines through immunization programs, while promoting preventive measures that combine VIA screening with vaccination. This approach will help developing countries, including China, achieve the goal of eliminating cervical cancer."

HEOR • Journal • Cervical Cancer • Oncology • Solid Tumor

IL-12 Synergistically Enhances HPV E7 mRNA Vaccine Efficacy by Promoting Effector T Cells and overcoming Exhaustion: Impact of Nucleotide Modification (ESMO-IO 2025) - "Cervical cancer and head and neck cancer (HNC) remain major health threats, particularly in low-income countries, whereas the availability of Gardasil has reduced infection rates in high-income regions...Moreover, nucleotide modification with N1-methylpseudouridine improved vaccine performance, underscoring its importance in mRNA cancer immunotherapy. These findings support the development of combinatorial mRNA vaccines as a promising approach for HPV-related cancers, especially in regions with limited access to conventional vaccines.Legal entity responsible for the study The authors."

Clinical • IO biomarker • Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor • IL12A

The vaccination status and attitudes toward human papillomavirus among gynecologists in China: A cross-sectional survey. (PubMed, Hum Vaccin Immunother) - "The vaccination rate among female gynecologists was 46.07% (223/484), with the quadrivalent HPV vaccine being most common at 40.36%...83.13% (468/563) gynecologists supported male vaccination.The level of support for vaccinating underage daughters was significantly higher than that for sons (87.74% vs. 68.92%, p<.001). It is essential to enhance public awareness of the protective benefits of HPV vaccination for males and its efficacy in preventing various diseases beyond cervical cancer."

Journal • Cervical Cancer • Endocrine Disorders • Oncology • Solid Tumor

CervALONE: A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia (clinicaltrials.gov) - P4 | N=1266 | Not yet recruiting | Sponsor: International Agency for Research on Cancer

Head-to-Head • New P4 trial

Should routine HPV vaccination programs include males 25-29 years? A systematic review and global meta-analysis. (PubMed, J Transl Med) - "This study demonstrates that extending HPV vaccination to males aged 25-29 years provides both individual and population-level benefits, particularly in settings with suboptimal female coverage. These findings support the inclusion of this demographic in vaccination programs and suggest that revising current age-restrictive policies could contribute to global efforts to eliminate HPV-related diseases. Future research should focus on real-world data to further strengthen the evidence base."

Clinical • Journal • Retrospective data • Review • Dermatology • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology • Pediatrics

Post-attachment neutralization of HPV16 by antibodies derived from Gardasil-vaccinated women. (PubMed, NPJ Vaccines) - "Using sera and memory B cell-derived monoclonal antibodies from Gardasil-vaccinated women, we observed almost complete post-attachment neutralization of HPV16 pseudovirion infection of HaCaT cells three hours after attachment, even when vaccinees' sera were diluted 250-fold, with a gradual loss of activity up to 18 h. Unexpectedly, three distinct mechanisms of post-attachment neutralization were discovered, capsid shedding from the cell surface, capsid retention on the cell surface, and rapid capsid degradation after internalization."

Journal • Human Papillomavirus Infection • Infectious Disease

Eruptive Seborrheic Keratoses Following Hpv Vaccination During Ixekizumab Therapy for Psoriasis: A Case Report and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "We report the case of a 37-year-old female with psoriasis who, after achieving stable disease control on ixekizumab, developed widespread eruptive brown macules, patches, and papules within one month of receiving a quadrivalent HPV vaccine...The lesions faded following oral acitretin therapy...We discuss potential mechanisms, propose clinical management considerations, and provide insights that may inform future research and clinical practice. The ultimate aim is to contribute to the refinement of guidelines on vaccination in patients receiving biologic therapy for psoriasis, ensuring both therapeutic efficacy and patient safety."

Journal • Dermatology • Immunology • Oncology • Psoriasis • IL17A

TheraVACCS: Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (clinicaltrials.gov) - P3 | N=52 | Completed | Sponsor: University of Pretoria | Active, not recruiting ➔ Completed | N=75 ➔ 52 | Trial completion date: Jul 2027 ➔ Jul 2025 | Trial primary completion date: Jul 2026 ➔ Jul 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Dermatology • Oncology • CD4

Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States (ISPOR-EU 2025) - "Despite 53% of respondents having received Gardasil and 47% previously treated with bevacizumab, disease burden remained high. Adult patients with RRP report a substantial physical burden that impacts mental well-being, work productivity, and overall QoL, particularly in those with frequent surgeries. These findings highlight the need for targeted therapies to reduce disease burden and improve patient outcomes."

Clinical • Mood Disorders • Psychiatry

GLOBE-HPV: SELF-COLLECTED FIRST-VOID URINE-BASED HUMAN PAPILLOMAVIRUS GENOMIC SURVEILLANCE AMONG WOMEN IN BANGLADESH (IPVC 2025) - "Among HPV-positive individuals, 13.3% (n=32) carried types covered by the quadrivalent vaccine (4vHPV), 24.5% (n=59) by the nonavalent vaccine (9vHPV) types, while 75.5% (n=182) carried at least one HPV type and 36.5% (n=88) HR-HPV, which are not targeted by available vaccines. This study provides updated data on HPV types among Bangladeshi women using self-collected FVU samples. The high genetic diversity and prevalence of nonvaccine HPV types highlight the need for ongoing surveillance and strengthened screening efforts, as the national program currently offers only a bivalent HPV vaccine."

Clinical • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

ENHANCING HPV VACCINE EQUITY IN LAO PDR: REACHING OUT-OF-SCHOOL GIRLS THROUGH INTEGRATED DELIVERY STRATEGIES. (IPVC 2025) - "Introduction: Since the introduction of the quadrivalent HPV vaccine into Lao PDR's National Immunization Program in 2020, overall coverage has remained below the 95% target, with persistent gaps among out-of-school girls... The integrated strategies led to significant improvements in HPV vaccine uptake among out-of-school girls in Lao PDR. Key enablers included enhanced enumeration processes, community mobilization, and strengthened supply and data systems. Sustaining and scaling these approaches, alongside ongoing efforts to improve population data accuracy, are underway as they are essential for achieving equitable and sustained HPV vaccination coverage in Laos."

PSYCHOSOCIAL BURDEN OF ANOGENITAL WARTS AMONG ADULTS IN CHINA: A QUALITATIVE STUDY (IPVC 2025) - "Introduction: Anogenital warts (AGW) are a vaccine-preventable condition caused primarily by human papillomavirus (HPV) genotypes 6 and 11, which are targeted by the quadrivalent (4vHPV) and nonavalent (9vHPV) vaccines. AGW imposes a substantial and multidimensional burden on patients' mental health, sexual well-being, and intimate relationships. These findings highlight the need to address the psychological and psychosexual burden of AGW in both clinical care and public health settings. Enhanced health education and expanded HPV vaccination efforts are essential to prevent AGW, alleviate its impact on quality of life, and reduce associated stigma."

Clinical • CNS Disorders • Dermatology • Fatigue • Mood Disorders • Pruritus • Psychiatry

FEASIBILITY AND ACCEPTABILITY OF HPV VACCINATION AMONG WOMEN LIVING WITH HIV AND THEIR DAUGHTERS IN INDIA: INSIGHTS FROM A MULTISITE PILOT INITIATIVE (IPVC 2025) - "A total of 670 eligible individuals aged 9–25 years were enrolled, receiving 1,296 doses of the quadrivalent HPV vaccine (Gardasil-4)... This pilot demonstrates that integrating targeted HPV vaccination within ART infrastructure, supported by individualized counselling and community engagement, is both feasible and effective in improving vaccine uptake among WLHIV and at-risk youth. The findings provide actionable insights to inform the design and scale-up of equitable, context-specific cervical cancer prevention strategies at the national level."

Clinical • Cervical Cancer • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

MOBILIZING GRASSROOTS CHAMPIONS TO ELIMINATE CERVICAL CANCER IN NIGERIA: GENERATING HPV VACCINE DEMAND THROUGH COMMUNITY-DRIVEN ENGAGEMENT (IPVC 2025) - "In October 2023, Nigeria introduced the quadrivalent HPV vaccine into its routine immunization schedule for girls aged 9–14, aligning with the national cervical cancer elimination strategy... Community-led mobilization through trusted local influencers is an effective and scalable model for increasing HPV vaccine demand. CSO-led engagement addresses last-mile delivery barriers and supports Nigeria's broader effort to eliminate cervical cancer by 2030. The success of this model underscores the importance of investing in grassroots structures/partnerships that foster community ownership, cultural alignment, and sustained behavioral change."

Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

HUMAN PAPILLOMAVIRUS INFECTION RATE AND ASSOCIATED LESIONS IN WOMEN AGED 16-45 YEARS WHO RECEIVED HPV VACCINE FROM 2016 TO 2022 (IPVC 2025) - " Among the 1622 women received vaccination, 255 (15.7%) received the bivalent HPV vaccine, 996(61.4%)received the quadrivalent HPV vaccine, and 371 (22.9%) received the nine-valent HPV vaccine... Cervical cancer screening is required after HPV vaccination, especially for women who have had sex before vaccination but have not been screened. Regular checkups are recommended for women with HPV infection prior to vaccination."

Clinical • Cervical Cancer • Cervical Squamous Cell Carcinoma • Human Papillomavirus Infection • Infectious Disease • Solid Tumor • Squamous Cell Carcinoma

HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE AMONG WOMEN IN THE GENERAL POPULATION IN LAKE VICTORIA ZONE, NORTH-WESTERN TANZANIA: GLOBE HPV BASELINE RESULTS (IPVC 2025) - "Tanzania initiated a national HPV vaccination programme in 2018, targeting 14-year-old girls with the 4-valent vaccine (Gardasil®)... A high prevalence of HPV infection was observed among women aged 25-35 years with multi-type and HR infections being common. Of the most prevalent HPV types, only one (HPV 16) is included in current vaccine formulation used in Tanzania. These HPV prevalence estimates obtained from an unvaccinated population can be used to assess the impact of HPV vaccination in subsequent population-level HPV surveys."

Clinical • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

ACTIVELY PROMOTE THE VACCINATION OF HUMAN PAPILLOMAVIRUS VACCINE IN CHINA (IPVC 2025) - " At present, there are 5 HPV vaccines in China, including bivalent vaccine (Cervarix, Cecolin and Wozehui), 4-valent and 9-valent vaccine (Gardasil 4 and 9), for women aged 9 to 45 ys,and for men aged 9 to 26y (4-valent), and 16 to 26ys(9-valent ). Now we have face big challenges to eliminate cervical cancer, With the combination of HPV vaccination and cervical cancer screening, China is accelerating the elimination of cervical cancer."

Cervical Cancer • Infectious Disease • Solid Tumor

EFFECTIVENESS OF THE NORWEGIAN HPV VACCINATION PROGRAMME 9 YEARS AFTER IMPLEMENTATION (IPVC 2025) - "Introduction: In Norway, quadrivalent HPV vaccine was implemented in the childhood immunisation programme in 2009, targeting 12-year-old girls... In this large population-based study, we observed a sustained high VE, both against vaccine types and nonvaccine types nine years after vaccination. The VE decreased with increasing age at vaccination, underscoring the importance of early vaccination."

HPV VACCINE EFFECTIVENESS AGAINST CERVICAL CANCER AND PRECANCER IN JAPAN: A TEST-NEGATIVE CASE–CONTROL STUDY (IPVC 2025) - "Introduction: Japan's human papillomavirus (HPV) immunization program for girls aged 12-16 years started in 2010 with the 2-valent vaccine (Cervarix). The 4-valent vaccine (Gardasil) was next introduced to the immunization program in 2011, while the 9-valent vaccine (Gardasil 9) was just recently introduced in 2023... These results indicate the real-world effectiveness of the 2- or 4-valent HPV vaccines after the introduction of the national immunization program in Japan."

Clinical • Cervical Cancer • Gynecology • Oncology • Solid Tumor

A WECHAT-DELIVERED IMB INTERVENTION TO IMPROVE HPV VACCINE ACCEPTABILITY AMONG CHINESE MSM: A RANDOMIZED CONTROLLED TRIAL (IPVC 2025) - "Following the January 2025 approval of Gardasil® for males, culturally appropriate interventions are now critically needed to address potential barriers to vaccine uptake in this population... A brief, WeChat-delivered IMB intervention significantly enhances short-term HPV vaccine acceptability among Chinese MSM. To sustain impact, future interventions must address temporal reduction and structural barriers like cost and stigma."

Clinical • Human Immunodeficiency Virus • Infectious Disease

COMPARATIVE STUDIES OF CYTOKINE AND HISTOLOGICAL PROFILES AMONG TWO HPV VACCINES: HPV VACCINE ADJUVANTS WERE SAFE AND IRRELEVANT TO CLINICAL SIGNS OR BRAIN PATHOLOGY (IPVC 2025) - "Neither 2vHPV nor 4vHPV induced neurological deficits or damage in any organs, irrelevant to cytokine profiles. Continuously high levels of IFN-β in vHPV groups may protect against other viral infections by trained immunity. Lastly, 2vHPV containing adjuvant AS04 (AH and MPL) and did not induce weight loss; QS-21, but not MPL, in adjuvant AS01 seemed responsible for weight loss, demonstrating the safety of MPL."

Clinical • Hepatitis B • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Varicella Zoster • IFNB1

ASSESSMENT OF THE QUADRIVALENT HPV VACCINE EFFECTIVENESS IN CÔTE D'IVOIRE: PRELIMINARY RESULTS FROM A SCHOOL-BASED PILOT STUDY (IPVC 2025) - "The observed reduction in the prevalence of HPV-16/18 among vaccinated participants supports the vaccine's potential to significantly contribute to cervical cancer prevention efforts in this population."

Clinical • Cervical Cancer • Solid Tumor

FIJI - 3 HPV STUDIES ON VACCINE EFFECTIVENESS, INCLUDING 1 DOSE EVIDENCE IN HMIC (IPVC 2025) - "A single 4vHPV dose induces persistent antibodies and provides substantial protection against HPV 16/18. Long-term follow-up is essential to inform single-dose HPV vaccination strategies globally. Fiji's third study[2025-2027] will provide value added evidence towards this and likely to be the longest global analysis thus far."

PREVALENCE AND DISTRIBUTION OF HIGH-RISK HPV GENOTYPES IN WOMEN ATTENDING PRIMARY HEALTH CARE IN RIO DE JANEIRO (IPVC 2025) - "Since 2014, the quadrivalent HPV vaccine (types 6, 11, 16, 18) was introduce in the public health system... The most predominant high-risk viral genotypes were different from those present in the quadrivalent vaccine, highlighting the positive impact of the vaccine after 10 years of implementation in public health care. Understanding which HPV genotypes are predominant in Rio de Janeiro is essential for defining new strategies for CC prevention."

Clinical • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Long-acting Reversible Contraceptives • Solid Tumor